Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2021 07:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Third Quarter Financial Results

CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help...
October 22, 2021 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic...
September 09, 2021 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
August 24, 2021 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic...
August 20, 2021 09:25 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

$5.2M invested at $3.45 stock priceFunds to be used to advance clinical development of LB1148Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used...
July 29, 2021 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

Statistically significant 1.1-day acceleration in return of bowel function Favorable overall safety profile in 120 patients CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) --...
July 13, 2021 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development

CARLSBAD, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
June 15, 2021 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions

CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
May 13, 2021 07:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery...
December 19, 2018 02:04 ET | Source: Neuralstem, Inc.

ニューラルステム、ケン･カーター博士を取締役会の常務会長に任命

メリーランド州ジャーマンタウン発, Dec. 19, 2018 (GLOBE NEWSWIRE) -- 神経幹細胞および小分子テクノロジーを基盤とする神経系治療の開発を専門にしているバイオ医薬品会社、ニューラルステム (Neuralstem, Inc.、Nasdaq: CUR) は本日、ケン･C･カーター博士 (Kenneth C. Carter, Ph.D.)...